BioCryst Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $117,085 | $109,332 | $92,761 | $93,401 |
Gross Profit | 113,857 | 107,278 | 91,496 | 91,341 |
EBITDA | 11,692 | 9,081 | -10,202 | -38,156 |
EBIT | 11,381 | 8,761 | -10,508 | -38,579 |
Net Income | -14,033 | -12,674 | -35,379 | -61,731 |
Net Change In Cash | 117,085 | 109,332 | 92,761 | 93,401 |
Free Cash Flow | 8,186 | -1,925 | -53,919 | -9,472 |
Cash | 96,841 | 80,205 | 84,333 | 112,447 |
Basic Shares | 206,905 | 206,425 | 206,064 | 201,409 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $331,412 | $270,827 | $157,170 | $17,812 |
Gross Profit | 326,751 | 264,233 | 149,906 | 16,136 |
EBITDA | -116,335 | -143,854 | -121,738 | -167,565 |
EBIT | -117,990 | -145,291 | -122,515 | -168,313 |
Net Income | -226,539 | -247,117 | -184,062 | -196,567 |
Net Change In Cash | 331,412 | 270,827 | 157,170 | 17,812 |
Cost of Revenue | 233,386 | 158,625 | ||
Free Cash Flow | -97,309 | -163,201 | -144,542 | -137,730 |
Cash | 110,643 | 304,767 | 504,389 | 272,127 |
Basic Shares | 192,198 | 185,908 | 179,117 | 167,267 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.07 |
2024-06-30 | -$0.06 |
2024-03-31 | -$0.17 |
2023-12-31 | -$0.28 |
